This brand name is authorized in Estonia, Ireland, Lithuania, Poland, United States
The drug COPIKTRA contains one active pharmaceutical ingredient (API):
1
Duvelisib
UNII 610V23S0JI - DUVELISIB
|
Duvelisib is an inhibitor of PI3K with inhibitory activity predominantly against PI3K-δ and PI3K-γ isoforms expressed in normal and malignant B-cells. Duvelisib induced growth inhibition and reduced viability in cell lines derived from malignant B-cells and in primary CLL tumor cells. Duvelisib inhibits several key cell-signaling pathways, including B-cell receptor signaling and CXCR12-mediated chemotaxis of malignant B-cells. Additionally, duvelisib inhibits CXCL12-induced T cell migration and M-CSF and IL-4 driven M2 polarization of macrophages. |
Below package inserts are available for further reading:
Title | Information Source | Document Type | |
---|---|---|---|
COPIKTRA Capsule | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
COPIKTRA Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC code | Group title | Classification |
---|---|---|
L01EM04 | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
Country: EE | Ravimiamet | Identifier(s): 1849305, 1849316 |
Country: LT | Valstybinė vaistų kontrolės tarnyba | Identifier(s): 1092668, 1092669 |
Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100455394, 100455407 |
Country: US | FDA, National Drug Code | Identifier(s): 71779-115, 71779-125 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.